Irhythm Technologies Inc (IRTC) Stock Price, Quote & News

Company Profile

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) moni...

Industry: Medical Devices

Sector: Healthcare

Phone: 415 632 5700

Website: www.irhythmtech.com

Address:

699 8th Street, Suite 600, San Francisco, United States

11thestate Aug. 12 at 1:24 PM

$IRTC Investors: $45M Settlement Now Accepting Claims A $45M settlement has been reached in the iRhythm case involving claims about its Zio AT device, including data accuracy and its use in high-risk patients. The company later faced FDA and DOJ scrutiny over the device. Eligible $IRTC investors who purchased shares between 2022 and 2024 can now submit a claim: https://11th.com/cases/irhythm-investor-settlement

0 · Reply

StocktwitsEarnings Aug. 6 at 8:27 PM

$IRTC Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.01 up 97.73% YoY • Reported revenue of $224.17M up 20.08% YoY • For the full year 2026, iRhythm Technologies Inc. expects revenue between $880 million and $890 million and adjusted EBITDA margin between 13.0% and 14.0%, reflecting volume-led growth and gross margin expansion.

0 · Reply

RockyTSTH Aug. 6 at 8:07 PM

$IRTC iRhythm Technologies Q2 Adj. EPS $0.58 Beats $(0.00) Estimate, Sales $224.172M Beat $219.324M Estimate

0 · Reply

Estimize Aug. 6 at 3:01 PM

$IRTC reports after the close, Estimize Consensus +0.08 EPS and +6.33M Revs compared to WS http://www.estimize.com/irtc/fq2-2026?utm_conten

0 · Reply

11thestate Jul. 16 at 4:22 PM

$IRTC investors there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/irhythm-investor-settlement

0 · Reply

11thestate Jul. 1 at 2:20 PM

Imagine buying $IRTC at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $IRTC investors out there, we’ve got some important news: a $45 million investor settlement is now open for claims from shareholders who purchased shares between 2022 and 2024. You can check if you’re eligible and claim your share: https://11th.com/cases/irhythm-investor-settlement

0 · Reply

11thestate Jun. 8 at 2:43 PM

Settlement Update: iRhythm Technologies ($IRTC) The proposed $45M iRhythm settlement has advanced to the Stipulation of Settlement stage, meaning the parties have formally agreed to resolve the case and are now seeking court approval. The case covers investors who purchased $IRTC shares between July 25, 2022 and August 29, 2024. We have every detail, including how investors can get paid: https://11th.com/cases/irhythm-investor-settlement

0 · Reply

MarketBeat May. 18 at 11:03 AM

https://marketbeat.com/a/8661047/ $IRTC iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains

0 · Reply

BillionerOfKing May. 5 at 9:42 PM

$IRTC Current Stock Price: $118.11 Contracts to trade: $120.0 IRTC May 15 2026 Call Entry: $2.35 Exit: $3.21 ROI: 37% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday May. 1 at 3:42 PM

$IRTC Share Price: $120.50 Contract Selected: Nov 20, 2026 $140 Calls Buy Zone: $8.84 – $10.92 Target Zone: $14.47 – $17.69 Potential Upside: 55% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	5.78B
Revenue (ttm)	591.84M
Net Income (ttm)	-113.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-19.14%
Debt to Equity Ratio	0.00

Volume	1,454,100
Avg Vol	495,702
Day's Range	N/A - N/A
Shares Out	32.22M
Stochastic %K	35%
Beta	1.12
Analysts	Strong Sell
Price Target	$219.64